Evidence map›Paper›PMID 36790881›Full record

Trial reportAmerican journal of respiratory and critical care medicine2023

A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials.

Ekaterina V Kurbatova, Patrick P J Phillips, Susan E Dorman, Erin E Sizemore, Kia E Bryant, Anne E Purfield, Jessica Ricaldi, Nicole E Brown, John L Johnson, Carole L Wallis and 20 more

Registry-linked trialOpen access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of respiratory and critical care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07018076 (Candidate Clinical Correlate of Prognostic Outcome for TB Study), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07018076 recruitingnot on this mapstarted 2025, after this paper: background citation

Candidate Clinical Correlate of Prognostic Outcome for TB Study

TypeobservationalSponsorUniversity of California, San FranciscoRan2025 to 2027Enrolled750ConditionsTuberculosisArmsRS ratio, Blood-based host immune response assays
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors at 15 institutions in 6 countries.

Ekaterina V KurbatovaU.S. Centers for Disease Control and Prevention, Atlanta, Georgia.ORCID 0000-0003-4636-3731
Patrick P J PhillipsUCSF Center for Tuberculosis, University of California San Francisco, San Francisco, California.ORCID 0000-0002-6336-7024
Susan E DormanMedical University of South Carolina, Charleston, South Carolina.
Erin E SizemoreU.S. Centers for Disease Control and Prevention, Atlanta, Georgia.ORCID 0000-0003-3232-0546
Kia E BryantU.S. Centers for Disease Control and Prevention, Atlanta, Georgia.ORCID 0000-0003-0785-7800
Anne E PurfieldU.S. Centers for Disease Control and Prevention, Atlanta, Georgia.
Jessica RicaldiU.S. Centers for Disease Control and Prevention, Atlanta, Georgia.
Nicole E BrownU.S. Centers for Disease Control and Prevention, Atlanta, Georgia.ORCID 0000-0002-3184-0550
John L JohnsonCase Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, Ohio.ORCID 0000-0003-1783-0476
Carole L WallisLancet Laboratories and Bio Analytical Research Corporation South Africa (BARC SA), Johannesburg, South Africa.
Joseph P AkolUganda-Case Western Reserve University Research Collaboration, Kampala, Uganda.
Oksana OcheretinaGHESKIO, Port-au-Prince, Haiti.ORCID 0000-0002-6736-3362
Nguyen Van HungVietnam National Tuberculosis Program/National Lung Hospital, Hanoi, Vietnam.
Harriet Mayanja-KizzaUganda-Case Western Reserve University Research Collaboration, Kampala, Uganda.
Madeleine LourensTASK, Cape Town, South Africa.
Rodney DawsonDivision of Pulmonology, Department of Medicine, University of Cape Town and University of Cape Town Lung Institute, Cape Town, South Africa.
Nguyen Viet NhungVietnam National Tuberculosis Program/National Lung Hospital, Hanoi, Vietnam.
Samuel PierreGHESKIO, Port-au-Prince, Haiti.
Yeukai MusodzaUniversity of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Justin ShenjeSouth African Tuberculosis Vaccine Initiative, Cape Town, South Africa.ORCID 0000-0003-3054-3930
Sharlaa Badal-FaesenClinical HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0002-7306-5732
Stalz Charles VilbrunGHESKIO, Port-au-Prince, Haiti.
Ziyaad WajaPerinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0001-8717-9039
Lakshmi PeddareddyU.S. Centers for Disease Control and Prevention, Atlanta, Georgia.
Nigel A ScottU.S. Centers for Disease Control and Prevention, Atlanta, Georgia.
Yan YuanU.S. Centers for Disease Control and Prevention, Atlanta, Georgia.
Stefan V GoldbergU.S. Centers for Disease Control and Prevention, Atlanta, Georgia.ORCID 0000-0002-8513-7342
Susan SwindellsUniversity of Nebraska Medical Center, Omaha, Nebraska; and.ORCID 0000-0001-5826-6037
Richard E ChaissonJohns Hopkins University School of Medicine, Baltimore, Maryland.
Payam NahidUCSF Center for Tuberculosis, University of California San Francisco, San Francisco, California.ORCID 0000-0003-2811-1311
Centers for Disease Control and Prevention · USGheskio Centers · HTHanoi Lung Hospital · VNMUJHU Research Collaboration · UGUniversity of California, San Francisco · USUniversity of the Witwatersrand · ZAJohns Hopkins University · USLancet Laboratories · ZAMedical University of South Carolina · USSouth African Tuberculosis Vaccine Initiative · ZATask Applied Science · ZAUniversity Hospitals of Cleveland · USUniversity of Cape Town · ZAUniversity of Nebraska Medical Center · USUniversity of Zimbabwe · ZW

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
NIAID NIH HHS U01 AI068636NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069432NIAID NIH HHS UM1 AI069463NIAID NIH HHS UM1 AI106701
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

TuberculosisTuberculosis, PulmonaryAntitubercular AgentsHumansAntitubercular Agentsendpoints ascertainment biasmulticenter randomized trialnoninferiorityoutcomesTB

Identifiers

PMID36790881
PMCPMC10595436
OpenAlexW4320857740

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.